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Correct mRNA Processing at a Mutant TT Splice Donor
in FANCC Ameliorates the Clinical Phenotype in Patients
and Is Enhanced by Delivery of Suppressor U1 snRNAs
Linda Hartmann,1 Kornelia Neveling,2 Stephanie Borkens,1 Hildegard Schneider,3 Marcel Freund,3
Elke Grassman,4 Stephan Theiss,5 Angela Wawer,6 Stefan Burdach,6 Arleen D. Auerbach,7
Detlev Schindler,2 Helmut Hanenberg,3,8,9,* and Heiner Schaal1,9,*
The U1 small nuclear RNA (U1 snRNA) as a component of the major U2-dependent spliceosome recognizes 50 splice sites (50ss) contain-
ing GT as the canonical dinucleotide in the intronic positions þ1 and þ2. The c.165þ1G>T germline mutation in the 50ss of exon 2 of
the Fanconi anemia C (FANCC) gene commonly predicted to prevent correct splicing was identified in nine FA patients from three pedi-
grees. RT-PCR analysis of the endogenous FANCCmRNA splicing pattern of patient-derived fibroblasts revealed aberrant mRNA process-
ing, but surprisingly also correct splicing at the TT dinucleotide, albeit with lower efficiency. This consequently resulted in low levels of
correctly spliced transcript and minute levels of normal posttranslationally processed FANCD2 protein, indicating that this naturally
occurring TT splicing might contribute to the milder clinical manifestations of the disease in these patients. Functional analysis of
this FANCC 50ss within splicing reporters revealed that both the noncanonical TT dinucleotide and the genomic context of FANCC
were required for the residual correct splicing at thismutant 50ss. Finally, use of lentiviral vectors as a delivery system to introduce expres-
sion cassettes for TT-adapted U1 snRNAs into primary FANCC patient fibroblasts allowed the correction of the DNA-damage-induced G2
cell-cycle arrest in these cells, thus representing an alternative transcript-targeting approach for genetic therapy of inherited splice-site
mutations.Introduction
Fanconi anemia (FA) is an autosomal or X-linked recessive
inherited DNA instability disorder that is caused by germ-
line mutations in at least thirteen genes (FANCA [MIM
607139], FANCB [MIM 300515], FANCC [MIM 227645],
FANCD1 [MIM 600185], FANCD2 [MIM 227646], FANCE
[MIM 600901], FANCF [MIM 603467], FANCG [MIM
602956], FANCI [MIM 609053], FANCJ [MIM 609054],
FANCL [MIM 608111], FANCM [MIM 609644], and FANCN
[MIM 610355]) involved in DNA-damage response.1–3 The
heterogenous clinical phenotype of this disease is charac-
terized by variable congenital abnormalities, progressive
bonemarrow failure, and a predisposition tomalignancies,
primarily acute myelogenous leukemia (AML [MIM
601626]) and solid tumors.4–8 Cells from FA patients
exhibit a distinctive cellular phenotype of hypersensitivity
to DNA crosslinking agents such as mitomycin C (MMC)
and diepoxybutane (DEB), a phenotype that can be
assessed as increased chromosomal breakage in metaphase
analysis and as G2 cell-cycle arrest by flow cytometry.9–11
Defects in the FA pathway can be grouped into three
distinct categories based on the biochemical characteristics
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FANCE, FANCF, FANCG, and FANCL, whose protein prod-
ucts physically interact in a multiprotein core complex
including FANCM. The main function of this FA core
complex with E3 ubiquitin ligase activity appears to be
the posttranslational activations of FANCD2 and FANCI
by monoubiquitination of specific lysine residues.2,12
Phosphorylation of FANCD2 and FANCI and several other
core-complex members is also an essential regulatory step
in the FA pathway.13,14 The second group is formed by
FANCD2 and FANCI, which form dimers and in their func-
tion depend on each other.14–18 For FANCD2, we estab-
lished that despite the fact that all live-born patients
have at least one hypomorphic allele, the overall clinical
characteristics of biallelic germline defects are more severe
compared to the classical FA core genes.19 The third cate-
gory, in which FANCD2 and FANCI are normally ubiquiti-
nated, is formed by the late FA genes BRCA2(FANCD1)20
and the gene encoding its stabilizer PALB2(FANCN),21 by
the gene encoding the BRCA1-associated helicase BRIP1
(FANCJ),22 and probably also by the atypical FANCM.23
Defects in FANCD1 and FANCN are associated with the
most severe form of FA due to an extremely high incidence
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age.21,24,25 Little is known yet about the phenotypical
consequences of biallelic defects in FANCJ,22 FANCM,23
and the recently identified FA-like RAD51C (MIM
602774).26
Additional factors have been identified that considerably
influence the clinical phenotype in FA patients with germ-
line mutations in the same gene. Well established is the
impact of certain mutations in FANCC as the first FA
gene identified on the clinical manifestations and the
natural course of the disease.4 In the North American Inter-
national FA Registry (IFAR), the biallelic c.456þ4A>T
mutation (formerly IVS4þ4A>T), almost exclusively found
in the Ashkenazi-Jewish population, and the mutation
c.1642C>T (p.R548X) in FANCC are strongly correlated
with increased numbers of severe congenital malforma-
tion, earlier onsets of marrow failure, and overall poorer
survivals compared to the patients with the Northern
European exon 2 (c.67delC [p.Q13X]) FANCC and patients
with FANCA or FANCG mutations.4,27 Molecular analysis
demonstrated that this milder phenotype of the exon 2
mutation was due to the presence of an N-terminally trun-
cated FANCC protein with residual activity, TRP50, from
an internal translation initiation site (methionine 55) in
exon 2.28 This truncated FANCCwas not present in FANCC
c.456þ4A>T homozygous cells.28 Surprisingly, Futaki et al.
subsequently showed that the c.456þ4A>T mutation in
Japanese patients is not associated with a severe clinical
phenotype, demonstrating that the ethnic background
can be a major modifier of the clinical disease characteris-
tics.29 The clinical manifestations of FA are also influenced
by mutations that result in minute levels of normal
protein19,21,24,25,27,30–33 or in mutant proteins with
residual functions.28,34,35 Polymorphisms in detoxifier
genes may also play a role in the course of the disease.36,37
The mutation spectrum of germline mutations in FA
includes single-base-pair substitutions within splice sites,
either in the splice donor, also called 50 splice site (50ss),
or in the splice acceptor (30ss).19,21,25,27,32,33 The canonical
GT dinucleotide within the 50ss of the major U2-type
introns is found inmore than 99% of all annotated human
50ss.38,39 In 0.7% of human 50ss, GC is utilized as well.38,39
Both the GT-AG and GC-AG splice sites at exon-intron
boundaries are both processed by the U2-dependent spli-
ceosome including the U1, U2, U4/6, and U5 small nuclear
ribonucleoprotein particles (snRNPs; for review see 40). In
addition, a minor class of introns with AT-AC boundaries
coexist (<0.1% of annotated 50ss) and are excised by the
U12-dependent spliceosome composed of the snRNPs
U11, U12, U4atac/U6atac, and U5.41–43 Pathogenic 50ss
mutations affecting the canonical GT dinucleotide at posi-
tion þ1 are by far the most frequently diagnosed patho-
genic splice-site mutations, assumed to inevitably cause
aberrant splicing.44,45 Generally, for 50ss mutations, the
extent to which splicing is impaired depends on the weak-
ening of the RNA duplex that forms between the 50ss and
all 11 nucleotides of the 50-end of the endogenous U1 small
nuclear RNA (snRNA).46,47The AmericSince the seminal report in 1986,48 compensatory muta-
tions in U1 snRNA have been known to have the capability
to suppress 50ss mutations; however, to what extent which
nucleotide of the 50ss can be compensated is still unpredict-
able. Mutation-adapted U1 snRNAs designed to rescue
specific pathogenic mutations have been shown to partially
restore correct splicing of artificial minigene constructs in
established cell lines.49–51 So far, stable expression of engi-
neered U1 snRNA molecules correcting aberrant splicing
of endogenous mRNAs and thereby also the disease pheno-
type has not been reported for primary human cells.
Current gene therapy approaches for hematopoietic
disorders typically use lentiviral vector systems to insert
a wild-type cDNA copy of the mutant gene into hematopoi-
etic stem cells as target cells.52–54 For some genetic defects,
pursuing this strategy might not be feasible because of the
large size of the wild-type cDNA20 or the profound toxicity
of the overexpressed normal proteins.19,22 An alternative
approach for genetic therapies for mutations affecting
splicing is a mutation-specific correction of mRNA process-
ing that, incidentally, would allow the natural transcrip-
tional control of the affected gene to be maintained.
Here, we report the clinical and molecular consequences
of the c.165þ1G>T splice-donor mutation in intron 2 of
FANCC in patients from three FA families, a mutation
that converts the canonical GT into a TT dinucleotide.
Analysis of the endogenous FANCC splicing pattern of
patient-derived fibroblasts revealed correct mRNA process-
ing at this mutant splice donor resulting in low levels of
correctly spliced transcript and residual E3 ligase activity
of the partially reconstituted FA core complex. Functional
characterization of this 50ss mutation within minigene
constructs carrying FANCC exon 2 as the middle exon
revealed that both the overall complementarity of this
pathogenic 50ss to U1 snRNA and the genomic context
were required for correct splicing at this mutant splice
donor. In addition, we demonstrate that stable expression
of TT-adapted artificial U1 snRNAs is capable of correcting
the phenotype of primary FA patient fibroblasts. This
suggests that lentiviral delivery of a splice-donor-muta-
tion-adapted U1 snRNAs might be a viable alternative
strategy for genetic therapy of certain FA complementation
groups with founder mutations in 50ss.Material and Methods
Patients
Index patients from two Arabian families and one mixed Arabian/
British couple were diagnosed as affected by FA on the basis of
moderate clinical features (see Table 1) in combination with the
hypersensitivity of their primary skin fibroblasts to mitomycin C
(MMC)10 or diepoxybutane (DEB),9 respectively (data not shown).
One family with five affected children was treated at the Chil-
dren’s Hospital Schwabing, Technical University of Munich,
Germany. Two families were treated in North America or the
United Kingdom and enrolled in the International Fanconi
Anemia Registry (IFAR)4 of the Rockefeller University, New York.an Journal of Human Genetics 87, 480–493, October 8, 2010 481



















526/1 M c.165þ1G>T c.165þ1G>T Cafe´-au-lait spots 5.5 10.5 16 BMF Alive at 20 years,
3.5 years after SCT
526/2 F c.165þ1G>T c.165þ1G>T Cafe´-au-lait spots 8 1 9 BMF Alive at 29 years,
20 years after SCT
526/3 F c.165þ1G>T c.165þ1G>T Cafe´-au-lait spots 13 2 19 BMF Alive at 19.5 years,
0.5 years after SCT
526/4 F c.165þ1G>T c.165þ1G>T Cafe´-au-lait spots 6 - - Alive at 11 years of age
526/5 F c.165þ1G>T c.165þ1G>T Cafe´-au-lait spots 7.5 - - Alive at 8 years of age
640/1 M c.165þ1G>T c.1-250del Cafe´-au-lait spots,
malrotated kidney, ureter
duplication, microphallus
5.5 - - Died at 13.5 years of age
640/2 M c.165þ1G>T c.1-250del Cafe´-au-lait spots,
microphallus
7 8.5 15.5 BMF Died at 16 years of age
1159/1 M c.165þ1G>T c.165þ1G>T Cafe´-au-lait spots 11.5 1 12.5 BMF Died at 12.5 years of age
1159/2 F c.165þ1G>T c.165þ1G>T none none - Alive at 4.5 years of age
Shown are the clinical characteristics of the nine FA-C patients from three pedigrees numbered 526, 640, and 1159, respectively. The gender, the paternal and
maternal FANCC mutations, the cafe´-au-laits spots and the major congenital abnormalities, the age at the onset of bone marrow failure, the time interval from
diagnosis until stem cell transplantation, the age at and the indication for transplantation, and the last follow-up are shown.All families signed informed consent approved by the local ethics
committees.
Cells and FANCC Sequencing
Fibroblasts and genomic DNA samples were derived by standard
methods.55,56 Complementation studies with oncoretroviral
vectors containing normal FANCA, FANCC, FANCE, FANCF, and
FANCG cDNAs were performed at the Department of Pediatric
Hematology, Oncology, and Clinical Immunology, Children’s
Hospital, Heinrich-Heine-University, Du¨sseldorf, Germany, or at
the Translational Trials Development and Support Laboratory,
Experimental Hematology and Cancer Biology, Cincinnati Chil-
dren’s Hospital, similarly as described.11,57,58 Primary fibroblasts
were immortalized by transduction with a lentiviral vector
expressing the SV40 large T antigen (H.H., unpublished data).
FANCC sequencing was performed as described previously.59 The
maternally inherited genomic deletion leading to exon 2 and 3
skipping in the family 640 was detected on the transcriptional
level by use of the FANCC exon 1 (#3244) and exon 4 (#3245) or
exon 5 (#2911) primers, respectively, as described below under
RT-PCR Assay. The updated nomenclature for FANCC mutations
is based on the RefSeq number NM_000136.2.
Plasmids
FANCC exon 2 including 137 nucleotides of the upstream intron
and 22 nucleotides of the downstream intron was amplified
from genomic DNA by PCR in intron 1 and intron 2 listed in Table
S1A (available online) and inserted via EcoRI-XhoI into the three-
exon, two-intron splicing reporter construct described previ-
ously.60,61 Mutant derivatives were generated by PCR mutagenesis
with Pwo-Polymerase (Roche) and oligonucleotides carrying
mutations to generate mutated constructs (Table S1C). For
a second splicing reporter construct, the subgenomic region of
FANCC including 676 bp of the 30 part of intron 1, exon 2, intron
2, and exon 3 was amplified from control DNA by PCR with the
primers #3715 and #3717 (Table S1C) using Expand High Fidelity482 The American Journal of Human Genetics 87, 480–493, OctoberDNA Polymerase (Roche). The 50 splice-site mutation was intro-
duced by PCR mutagenesis with the primers #3718 and #3719
with the QuickChange XL Site-Directed Mutagenesis Kit (Strata-
gene). All constructs were controlled by sequencing.
For the construction of the mutation-adapted U1 snRNA expres-
sion plasmid pUCBU1aTT, the BglII-XhoI fragment of
pUCBDU147 was substituted for a PCR fragment amplified with
50-primer #2040 carrying the BglII site and the specific mutation
and the 30-primer #1131 and pUCBU1 (kindly provided by Alan
Weiner, Seattle, WA) as the template. For construction of the
pUCBU1-TTcom and pUCBU1mt, the BglII-XhoI fragment pUC-
BU1aTT was substituted for the PCR fragment amplified with 50-
primer #2809 and 30-primer #1131 and pUCBU1aTT as the
template. Oligonucleotides were synthesized as previously
described62 or were purchased from Metabion (Martinsried,
Germany). Sequences of all constructs are available on request.Cell Culture and Transfection
For the splicing reporter assay, 2.53 105 HeLa cells63 in Dulbecco’s
modified Eagle’s medium (DMEM; Invitrogen) supplemented with
10% fetal bovine serum (Pan Biotech), 2 mM L-glutamine, and
50 U/ml penicillin and streptomycin (both Invitrogen), were
seeded per 6-well plate 24 hr before transfection. Cells were trans-
fected with 1 mg of the splice reporter constructs or their mutated
derivatives with FuGENE 6 according to the manufacturer’s
protocol (Roche Molecular Biochemicals). For cotransfection
experiments, cells were transfected with 1 mg of pXGH5 encoding
human growth hormone64 and 2 mg of the respective plasmid.
Primary fibroblast strains were established by standard cell-
culture procedures and maintained in complete DMEM in high-
humidity incubators in an atmosphere of 5% (v/v) CO2 and 5%
(v/v) O2.
65 For splicing analysis of the endogenous FANCC tran-
script, fibroblasts were seeded in T75 flasks and grown to approx-
imately 80% confluency. For transfection of immortalized fibro-
blasts, cells were seeded 24 hr before transfection and
transfected with 16 mg of the respective plasmid and 8 mg of8, 2010
pXGH5 by using FuGENE 6 (Roche Molecular Biochemicals). For
both assays, RNA was isolated 30 hr after transfection.
RT-PCR Assay
To isolate total RNA, we used Gene Elute Mammalian Total RNA Kit
(Sigma-Aldrich). RT-PCRwas performedwith the SuperScript TM III
RT-PCR System with Platinum Taq Polymerase (Invitrogen). For
analysis of the splicing pattern, prior to reverse transcription, 4 mg
(for the endogenous FANCC transcript) or 1 mg of total RNA (for
the splicing reporter transcript) was subjected to DNase I digestion
with 10 U of DNase I at 70C for 5 min (Roche), and 2 ml of the
DNase I-digested RNA samples were reverse transcribed with Super-
Script TM III RT-PCR System with Platinum Taq Polymerase using
the 50 FANCC exon 1 primer #3244 and 30 FANCC exon 4 primer
#3245 or 30 FANCC exon 5 primer #2911 (Table S1B). As negative
control for remainingDNA contamination of each sample, a second
assaywas performedwith PlatinumTaq Polymerase (Invitrogen). As
a control for transfection efficiency, human growth hormone
(hGH) mRNA was detected with the primer pair #1273 and #1274
(Table S1B). Spliced mRNA expressed from the reporter construct
was amplifiedwith the primers #481 and #559 (Table S1B). To allow
semiquantitative assessment of the spliced endogenous transcripts,
PCR analysis was performed within the linear range. PCR products
were separated on 6% nondenaturing polyacrylamide gels, stained
with ethidium bromide, and visualized with the Lumi-Imager F1
(Roche Molecular Biochemicals).
FANCD2 Immunoblotting
FANCD2 immunoblotting was performed as described19 with
minor modifications: immortalized FA fibroblasts transduced
with the different vectors were seeded in T75 flasks and grown
to approximately 70% confluence and exposed to 2 mM hydroxy-
urea (HU, Sigma-Aldrich) for 24 hr.
Lentiviral-Vector Production
HEK 293T and HT1080 cells (CRL-12103; ATCC, Manassas, VA)
grown in complete DMEM medium were used to produce and
titrate the lentiviral vectors (LVs) carrying the U1 snRNA variants.
For the production of LVs, 6 3 106 293 T cells were plated per
10 cm cell-culture dish 24 hr prior to transfection (using polyethy-
lenimine [PEI, Aldrich]) with 6 mg of pCD/NL-BH,66 6 mg of an
expression plasmid coding for vesicular stomatitis virus G
protein,67 and 6 mg of pCL1NPB-U1. Supernatants were harvested
48 hr after transfection and filtered through a 0.45 mm filter. Func-
tional NEO titers of the LV vectors were determined in HT1080
cells, plated at 3.5 3 104 cells per well in 6-well plates the day
before, and then infected with different dilutions of the LV prepa-
rations. The next day, cells were washed and incubated for 7 days
with fresh medium containing 0.8 mg/ml G418 (Invitrogen).
Colonies were fixed with methanol and stained with methyl-
enblue. Titers were calculated as described previously,55,56 usually
obtaining 106–107 infectious virus particles/ml.
Phenotypic Correction of FANCC Fibroblasts
Primary patient-derived FANCC fibroblasts were transduced with
either pCL1NPB-U1 wt or mutant U1 snRNA derivatives, or as
control, withMFCPN andmurine stem cell virus (MSCV) at equiv-
alent multiplicities of infection.11 G418-resistant cells were
cultured for 72 hr with or without 33 nMofMMC (Sigma-Aldrich).
Cells were harvested by trypsinization and washed with 1% (w/v)
bovine serum albumin fraction V (BSA) in PBS (Invitrogen). TheThe Americcell pellets were resuspended in PBS and fixed overnight in 98%
ethanol at 20C. After centrifugation (600 3 g, 4C), resus-
pended cell pellets were incubated with 100 mg/ml RNase (Invitro-
gen) in PBS for 15 min at 37C. Cell pellets were resuspended in
staining buffer containing 0.5% (w/v) BSA and 10 mg/ml propidiu-
miodid (PI; Sigma) in PBS. DNA histograms were recorded with the
flow cytometer FACSCalibur (Becton Dickinson, Heidelberg,
Germany). Quantitative assessment was performed with the Mod-
Fit software (Verity Software House).Results
Mild Clinical Manifestations of FA in the Nine FA-C
Patients
For complementation-group assignment, primary skin
fibroblasts of three index FA patients from two consan-
guineous families of Arabian ancestry and one mixed
Arabian/British couple were transduced with gammaretro-
viral vectors expressing one of the following cDNAs:
FANCA, FANCC, FANCE, FANCF, or FANCG.11,57,58 Trans-
duced fibroblast cells were exposed to 33 nM of MMC for
3 days and then harvested for cell-cycle analysis by flow
cytometry as described previously.11,57,58 The cell-cycle
distribution of the fibroblasts revealed that overexpression
of the FANCC cDNA specifically corrected the character-
istic DNA crosslinker hypersensitivity of the patients’ cells
(data not shown). Table 1 shows the clinical features of the
nine FA-C patients. Among the four male and five female
patients, only the two patients from the family 640 with
mixed ethnic background had typical severe congenital
malformations as described for FA patients.27 Calculated
for all nine affected individuals, the mean number of
0.45 malformations per patient was similar to that
described for the ‘‘European’’ c.67delC mutation in exon
227 but different from the c.456þ4A>T (IVS4þ4A>T) and
c.1642C>T (p.R548X) mutations described in Ashkenazi
Jewish and North American patients.4,27
The c.165þ1G>T Splice-Donor Mutation in Primary
Cells of FA-C Patients Allowed Correct Splicing albeit
at a Reduced Level
Genomic sequencing confirmed that all three index
patients carried a base-pair substitution in the 50 splice
site (50ss) of FANCC exon 2, c.165þ1G>T, converting the
highly conserved GT dinucleotide within the 50ss of
FANCC exon 2 to a TT dinucleotide (Figures 1A and 1B).
Patients from the pedigrees 526 and 1159 were homozy-
gous for this point mutation, whereas patients from the
pedigree 640 carried a maternally inherited genomic dele-
tion (Table 1), leading to the skipping of exons 2 and 3 in
the FANCC mRNA (data not shown). For analysis of the
phenotypic consequence at the RNA level, RT-PCR analysis
on mRNA from primary patient fibroblasts from pedigree
526 was performed. In contrast to normal control, we
found four distinct splice products contributing to 33%,
27%, 25%, and 15% of the transcripts, respectively
(Figure 1C). Direct sequencing of the amplified productsan Journal of Human Genetics 87, 480–493, October 8, 2010 483
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Figure 1. Homozygous c.165þ1G>T
Splice-Donor Mutation in Primary Cells of
the Index FA-C Patient from Pedigree
526 Allowed Correct Splicing at Low Level
(A) Structure of the FANCC exons showing
the position of the c.165þ1G>T mutation
and the translational start codon in exon
2 (1st coding exon). The position of RT-
PCR primers is depicted.
(B) Sequence result of the genomic DNA
carrying the biallelic c.165þ1G>T
(IVS2þ1G>T) 50ss mutation.
(C) Semiquantitative RT-PCR analysis of
the splicing pattern of the FANCC mRNA
in normal (con) and patient-derived
primary fibroblasts (IVS2þ1G>T).
(D) Schematic drawing highlighting the
positions of the 50ss used in cells with the
biallelic c.165þ1G>T mutation and cDNA
sequencing results from primary patient-
derived fibroblasts.revealed that the three FANCC transcripts of aberrant size
either lacked the translational start codon because of skip-
ping of FANCC exon 2 (25%, skipping) or encoded mutant
open reading frames with premature translation termina-
tion (33% and 15%, cryptic GC and GT). Remarkably,
the fourth amplified product (27%, TT) was the normal
wild-type FANCC transcript (Figure 1D). Therefore, the
c.165þ1G>T splice-donor mutation still enabled normal
FANCC transcript processing, albeit at lower efficiency
compared to the wild-type canonical 50ss.
Increased Complementarity to U1 snRNA Specifically
Reconstituted Splicing at the TT Dinucleotide in
a Heterologous Splicing Reporter Construct
For systematic analysis of this unusual pathogenic FANCC
splice donor, the FANCC exon 2 with flanking intronic
nucleotides was inserted into a three-exon splicing
reporter construct (Figure 2A) that we have established
previously.60 HeLa cells were transfected with plasmids
carrying either the wild-type GT or mutant TT FANCC
exon 2 splice donor and analyzed for their splicing pattern
by RT-PCR analysis. Although the intrinsic strength of the
wild-type FANCC 50ss is relatively high, because of the high484 The American Journal of Human Genetics 87, 480–493, October 8, 2010degree of complementarity to the U1
snRNA (Figure 2C), the analytical gel
(Figure 2B) demonstrated that the
recognition of the wild-type FANCC
exon 2 was not as effective as expected
(lane 2) and that the mutant 50ss was
not recognized at all (lane 3). These
splicing patterns indicated a depen-
dency of correct exon 2 recognition
on the genomic context in FANCC
that was missing in this minigene
construct. To rank the intrinsic
strength of the wild-type FANCC
exon 2 splice donor among human50ss, we analyzed a representative group of 43,464 anno-
tated 50ss from constitutively spliced human exons with
the HBond algorithm.47,68 In this analysis, all annotated
human splice-donor sites had an average HBond score of
15.001 5 2.591 standard deviation (SD), compared to
the HBond score of 18.7 of this FANCC 50ss, which thereby
is ranked at the 92.3 percentile of all splice-donor sites in
this data set.
Since we and others have previously shown that
increasing the complementarity between a 50ss and the
U1 snRNA can improve the recognition of 50ss and can
compensate for the lack of supportive context,47,68 we
additionally changed positions 3 and 2 of the mutant
TT 50ss to nucleotides complementary to the 50-end of
the endogenous U1 snRNA (Figure 2C). As shown in
Figure 2B, lane 5, these two additional nucleotide adapta-
tions facilitated inclusion of the FANCC exon 2 with the
mutant TT splice donor. Direct sequencing of this splice
product, however, revealed that splicing in this reporter
transcript occurred not only at the TT dinucleotide at the
authentic exon-intron border but was also shifted to the
GT dinucleotide one position upstream of TT (Figure 2D,
TT com 3/2). The existence of this second transcript is
exon 1 exon 3FANCC
5‘ss
intron 1 intron 2
FANCC  TT auGuUAAGUAg
U1 snRNA GUGCAUUCAUA3‘ 5‘
com -3/-2  TT CAGuUAAGUAg
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Figure 2. Improved Complementarity to
U1 snRNA Reconstituted Splicing at the
TT Dinucleotide in a Heterologous
Splicing Reporter Construct
(A) Schematic drawing of the 2-intron
splicing reporter harboring the FANCC
exon 2 with its strong 50ss (HBS 18.7).
(B) RT-PCR analysis of transfected HeLa
cells. FANCC indicates the splicing reporter
constructs that harbor either the wild-type
GT 50ss (lane 2) or the TT 50ss (lane 3) found
in the FA-C patients; com 3/2 FANCC
denotes the 50ss with improved comple-
mentarity to U1 snRNA at positions 3
and 2. Dinucleotides that were tested at
the þ1 and þ2 positions in the constructs
with improved complementarity at posi-
tions 3 and 2 are indicated in the figure
(lanes 5 to 14). The spliced products are
schematically shown on the right.
(C) Pattern of the HBond formations
between the FANCC TT 50ss and U1 snRNA
and the improved version of this splice site
with enhanced complementarity to the
U1 snRNA at positions 2 and 3.
(D) Direct sequencing results of the spliced
PCR products. S denotes G or C, K denotes
G or T, W denotes A or T, and N denotes
any nucleotide.remarkable, because all available algorithms for splice-
donor sites unequivocally predict that the intrinsic
strength of the GT dinucleotide at 1 is very weak (e.g.,
the HBond score is 2.3) as a result of the low complemen-
tary to the U1 snRNA in this base-pairing frame.
To further clarify whether splicing at this artificially
improved TT 50ss is simply determined by the overall
complementarity to U1 snRNA or also by the position of
the GT in the 1 register, we generated reporter constructs
that carried different dinucleotides at positions þ1 and þ2
(Figure 2B). Noteworthy here is that the substitution of T at
position þ2 maintains the GT within the 1 register yet
reduces the overall complementarity to the endogenous
U1 snRNA in the original base-pairing frame. In contrast,
substitution of the mismatching T at position þ1 for A or
C does not affect the overall complementarity in the orig-
inal base-pairing frame but specifically destroys the GT in
the 1 register. Thus, if the GT in the 1 register is impor-
tant for recognition of the mutant TT 50ss, the TA dinucle-
otide that specifically increases U1 complementarity in the
1 register should allow more efficient splice-site recogni-
tion. As shown in Figure 2B, lanes 5 to 14, and confirmed
by sequencing (Figure 2D), splicing in this construct onlyThe American Journal of Human Geoccurred at the two physiological
splice-donor sites GT and GC or if
a TT dinucleotide was present at posi-
tion þ1 and þ2. These data demon-
strated that a mutant TT splice-donor
site can be functional in a heterolo-
gous context if this site is highlycomplementary to the U1 snRNA. These results also sug-
gested that the complementarity of the 1 GT register to
the U1 snRNA is of less importance, because the TA dinu-
cleotide despite higher complementarity did not allow
splicing at this site (Figure 2B, lane 6).
Artificial TT-Adapted U1 snRNA Improved Correct
mRNA Processing at the FANCC TT 50ss within the
Splicing Reporter
Because the mutant TT 50ss of FANCC exon 2 was recog-
nized only in the splicing reporter after increasing its
complementarity to the U1 snRNA, we next asked whether
compensatory mutations within the 50 end of the U1
snRNA would also enable usage of the mutant FANCC TT
50ss. To this end, two artificial U1 snRNAs were constructed
(Figure 3A): the U1 snRNA aTT contains a single compen-
satory mutation complementary to the TT dinucleotide,
and the fully complementary (TTcom) U1 snRNA TTcom
matches every position of the mutant FANCC TT 50 splice
site. Whereas cotransfecting HeLa cells with the wild-
type U1 snRNA and the minigene splicing reporter did
not alter the splicing pattern of the construct (Figure 3B,
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Figure 3. TT-Adapted U1 snRNA
Restored Usage of the FANCC TT 50ss
within the Minigene Splicing Reporter
(A) Schematic illustration of two specifi-
cally TT-adapted U1 snRNAs and sketch
of the HBond formation with the FANCC
TT 50 ss (positions are numbered). HBonds
are indicated by vertical lines. U1 snRNA
aTT contains a single compensatory muta-
tion whereas U1 snRNA TTcom was engi-
neered to be able to base-pair with each
position of the FANCC TT 50 splice site.
The mutant nucleotide at the 50 end of
U1 in each case is shown in bold.
(B) RT-PCRanalysis ofHeLa cells transfected
with the splicing reporter containing the TT
50ss found in the FA-C patients. U1 wt, U1
aTT, andU1TTcom indicate cotransfections
with the wild-type or TT-adaptedU1 snRNA
expression plasmid pUCBU1 (lanes 2 to 4).
RT-PCR analysis of hGH was performed to
monitor transfection efficiency.
(C) Sequence results of the splice junctions.partially restored recognition (8% and 12%, respectively)
of the mutant FANCC TT 50ss (Figure 3B, lanes 3 and 4).
Here, sequence analysis of the splice products confirmed
that splicing exclusively occurred at the correct exon-
intron border (Figure 3C).
Combining the results from the last two experimental
settings of fully adapting either the 50ss to the endogenous
U1 snRNA or the U1 snRNA to the mutant splice site was
striking: the exclusive use of the noncanonical TT as splice
site was not simply determined by the free energy of the
RNA duplex formed between the splice donor and the
matching U1 snRNA (which was identical in both cases)
but was predominantly dependent on the 50ss sequence
itself. Importantly, these results implied that ectopic
expression of a TT-adapted U1 snRNA will improve the
recognition of the mutant FANCC TT 50ss within the
endogenous FANCC transcript in patient-derived cells
without the risk of activating aberrant splicing at the GT
in the 1 register or elsewhere in the genome.Ectopic Expression of the TT-Adapted U1 snRNAs
Specifically Enhanced the Amount of the Endogenous
In-Frame Transcript in FA Patient-Derived Fibroblasts
Because the TT-adapted U1 snRNAs improved the usage of
the pathogenic FANCC TT 50ss in the reporter system, we486 The American Journal of Human Genetics 87, 480–493, October 8, 2010immortalized the primary fibroblasts
from pedigree 526 with a lentivirus
expressing the SV40 large T cDNA
and then analyzed whether transfec-
tion of the biallelic FANCC
c.165þ1G>T fibroblasts with the TT-
adapted U1 snRNA constructs
enhanced the levels of endogenous
TT-spliced in-frame transcripts. Byusing RT-PCR primers in the 50UTR and in exon 4 to distin-
guish the different endogenous FANCC transcripts in the
biallelic FANCC c.165þ1G>T patients’ cells (Figure 1A),
we showed that transfection of patient-derived fibroblasts
with the TT-adapted U1 snRNAs U1 aTT or the U1 TTcom
specifically increased the amount of the TT-spliced in-
frame transcript from 30% to 56% and 58%, respectively
(Figures 4A and 4B). Direct sequencing of both splice prod-
ucts confirmed that they were accurately spliced at the
correct exon-intron border (Figure 4C). Concomitantly,
the amount of all aberrantly spliced transcripts decreased,
indicating that the two mutant TT-adapted U1 snRNAs
were capable of improving exon recognition and thereby
facilitating production of the correct in-frame transcript.
Thus, ectopic expression of the TT-adapted artificial U1
snRNAs significantly increased the usage of the pathogenic
TT 50ss in the patients’ fibroblasts.Phenotypic Correction of FANCC-Mutant Fibroblasts
by Integrating Lentivirus-Mediated Expression
of TT-Adapted U1 snRNA
Permanent suppression of splice-donor mutations in
cells still actively dividing requires that themutation-adap-
ted U1 snRNA integrate into the genome of the mutant
cells. Because retroviruses are evolutionary optimized
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Figure 4. Ectopic Expression of the TT-
Adapted U1 snRNAs Specifically Enhanced
the Amount of the Endogenous In-Frame
Transcript in Fibroblasts from the Index
Patient in Pedigree 526
(A) RT-PCR analysis of endogenous tran-
scripts in normal (con) and in patient-
derived immortalized fibroblasts. Overex-
pression of the TT-adapted or wild-type
U1 snRNAs in patient-derived fibroblasts
is indicated at the top (lanes 4 to 6). RT-
PCR analysis of hGH was performed to
monitor transfection efficiency. GC corre-
sponds to usage of a cryptic GC splice site
downstream of FANCC exon 2, and GT
denotes the usage of a cryptic GT splice
site within FANCC exon 2. Skip denotes
skipping of FANCC exon 2, and TT indi-
cates the usage of the TT splice donor re-
sulting in the correct in-frame transcript.
(B) Quantification of the relative splice-site
usage in patient-derived immortalized
fibroblasts from three independent trans-
fection experiments (mean 5 standard
error of the mean).
(C) Sequence results of the splice junctions
of the TT spliced transcripts. The transfec-
tion of the corresponding U1 snRNA
expression plasmid is indicated above.gene-delivery systems for stably introducing foreign cDNA
into the cellular DNA, we transferred the two TT-adapted
U1 snRNA expression cassettes into a LV that coexpressed
the neomycin phosphotransferase (neoR) cDNA in the
opposite orientation (Figure 5A). To determine whether
expression for the TT-adapted U1 snRNAs achieved with
the LV construct was sufficient for phenotypic correction
of the DNA crosslinker hypersensitivity, we transduced
primary fibroblasts of the index patient from family 526
with vectors expressing the wild-type or the two mutant
U1 snRNAs. As controls, fibroblasts were transduced with
a retroviral vector expressing the wild-type FANCC cDNA
or the corresponding retroviral and lentiviral control
vectors, expressing the neoR cDNA only. G418-resistant
fibroblasts were exposed for 3 days to 33 nM MMC
and then analyzed by flow cytometry for their cell-cycle
distribution.
Transduction of the patient’s fibroblasts carrying the
pathogenic c.165 þ1G>T mutation on both alleles with
a retroviral vector containing the wild-type FANCC cDNA
(MFCPN) corrected the MMC-induced G2 arrest, whereas
cells transduced with the mock vector (MSCV) exhibited
a prominent G2 phase arrest typical for FA (Figure 5B).
Expression of both TT-adapted U1 snRNAs (aTT, TTcom)
in the LV vector significantly improved the MMC-induced
cell-cycle arrest whereas stable expression of the wild-type
U1 snRNA did not influence the cell-cycle distribution of
the primary cells (Figure 5B).
For further analyses, the G418-resistant primary fibro-
blasts from the index patient from pedigree 526 trans-The Americduced with the different constructs (Figure 5B) were
immortalized with a LV vector that expressed the SV40
large T antigen. RT-PCR analysis of the endogenous FANCC
transcript in these fibroblasts confirmed the correct usage
of the mutant TT splice donor c.165 þ1G>T, because
FANCC exon 2 recognition was clearly improved by lenti-
virus-mediated expression of both TT-adapted U1 snRNAs
(Figure 5C). An indication of a functional FA core complex
with normal FANCC as essential component is the mono-
ubiquitination of FANCD2 in response to exposure to DNA
interstrand crosslinking agents.69 Because FANCD2 immu-
noblot analysis on primary fibroblasts is difficult because
of the minute amounts of FANCD2 present, the immortal-
ized fibroblasts from Figure 5C were exposed to 2 mM
hydroxyurea for 24 hr and then protein harvested as pub-
lished.19,69 Results revealed that 526/1 fibroblasts (see
Table 1) with the biallelic FANCC c.165þ1G>T mutation
already had minute levels of monoubiquitinated protein
even in the absence of any further genetic modifications
of the cells (Figure 5D). This indicated that the low levels
of TT-spliced endogenous in-frame transcript encoded
residual functional FANCC that was active in the FA core
complex. Finally, results showed that transduction of the
FANCC c.165þ1G>T fibroblasts with each of the two TT-
adapted synthetic U1 snRNA expression constructs
increased the levels of monoubiquitinated FANCD2 corre-
sponding to the mRNA splice pattern shown in Figure 5C.
Whereas expression of U1 snRNA TTcom resulted in
FANCD2 monoubiquitination levels comparable to the
those induced by expression of the wild-type FANCCan Journal of Human Genetics 87, 480–493, October 8, 2010 487
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Figure 5. Phenotypic Correction of Primary Biallelic c.165þ1G>T FANCC Fibroblasts of the Index Patient from Pedigree 526 by
Lentivirus-Mediated Expression of TT-Adapted U1 snRNAs
(A) Scheme of the lentiviral vector introducing the U1 snRNA expression cassette into target cells.
(B) Cell-cycle distribution of primary G418R fibroblasts with the FANCC c.165þ1G>T mutation transduced with the different retroviral
vectors after exposure to 33 nM MMC for 72 hr by flow cytometry. Shown are the histograms of one representatitive analysis and the
means of two independent polyclonal transduced primary cell populations. Transduction of the FANCC-mutant fibroblasts with a lenti-
viral vector harboring the TT-adapted U1 snRNAs significantly improved the MMC-induced cell-cycle arrest close to levels achieved by
retroviral overexpression of the wild-type FANCC cDNA (MFCPN).
(C) RT-PCR analysis of the endogenous FANCC transcript in retro- or lentivirus transduced and subsequently immortalized 526 fibro-
blasts from (B) and quantitative assessment of splice-site usage from three independent RNA preparations (mean 5 SEM).
(D) FANCD2 immunoblot from retro- or lentivirus transduced and subsequently immortalized fibroblasts from pedigree 526 after expo-
sure to 2mMhydroxyurea for 24 hr. Themonoubiquitinated and the nonmodified forms of the FANCD2 protein are labeled as D2-L and
D2-S, respectively.
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cDNA (MFCPN) and present in the normal control (con),
expression of the U1 aTT was less effective on both the
mRNA and the protein level (Figures 5C and 5D).
These data indicated that lentivirus-mediated stable
expression of TT-adapted U1 snRNA molecules can lead
to continuous production of sufficient amounts of endog-
enous functional FANCC transcript for restoration of the
FA pathway and correction of the cellular FA phenotype
of DNA crosslinker hypersensitivity, thus demonstrating
the potential of lentivirus-mediated transfer of splice-site-
mutation-adapted U1 snRNA genes as curative therapeutic
strategy for splice-donor site mutations in FA.Discussion
The phenotypic correction of primary fibroblasts from
three index FA patients by retroviral complementation
led to the identification of a biallelic 50ss mutation
c.165þ1G>T of the FANCC gene in two patients and
a monoalleic mutation in the third, confirming that
FANCC is the gene deficient in these three FA pedigrees.
RT-PCR analysis on primary fibroblasts with biallelic muta-
tions showed that the mutant TT 50ss resulted in aberrant
splicing, where the majority of transcripts (73%) were
nonfunctional because of exon skipping or the usage of
cryptic splice-donor sites. Unexpectedly, RT-PCR analysis
also revealed that this mutant TT 50ss facilitated correct
recognition of the normal exon-intron boundaries, leading
to reduced amounts of normal transcripts (27%).
In order to perform a systematic analysis of the mutant
TT 50ss in FANCC, we constructed a heterologous three-
exon, two-intron splicing reporter with FANCC exon 2 as
the middle exon. In HeLa cells, initial analyses of the
splicing pattern revealed that inclusion of the wild-type
exon was not exclusive and that the exon with the mutant
50ss was not recognized at all. This suggested that the
FANCC exon 2 recognition did not solely occur by exon
definition but also depended on additional flanking
sequences, both not present in the reporter construct. We
therefore substituted exon 2 and downstream reporter
sequences with authentic subgenomic FANCC sequences
from the 30-end of intron 1 up to exon 3. Transfection of
this reporter construct into HeLa cells clearly confirmed
that the genomic context of FANCC was also required for
efficient recognition of the FANCC exon 2 50ss (Figure S1B).
In our reporter system shown in Figure 2, exon recogni-
tion efficiency could be restored by additional nucleotide
substitutions in positions 3 and 2, thereby improving
the base-pairing with the U1 snRNA in the TT register.
This improved complementarity allowed us to demonstrate
that splicing specifically occurred only when GT, GC, or
the mutant TT dinucleotides were present at positions þ1
and þ2. Here, GT was the most and TT the least efficient
for correct mRNA processing. All other analyzed dinucleo-
tides at positions þ1 and þ2 did not support splicing at
this site. Sequencing of the RT-PCR-amplified TT-splicedThe Americtranscripts from this reporter construct also revealed addi-
tional splicing atposition1,whichhasbeen recently char-
acterized for the atypical 50ss and is assumed to precede
base-pairing in a shifted register.70 This additional splicing
at1 cannot simply be explained by the increased comple-
mentarity to the U1 snRNA in the 1 register, because the
TA dinucleotide in the splicing reporter that would other-
wise have specifically increased base-pairing to U1 snRNA
at 1 (gcaGTAAagta, HBond score 9.0 versus gcaGTtAagta,
HBond score 1.9) did not allow splicing (Figure 2B, lane
6). This suggested that the wild-type U1 snRNA paired
with the mutant FANCC TT splice donor in the canonical
register. As confirmation, in the natural context, however,
splicing of the mutant TT splice-donor site exclusively
occurred immediately upstream of the TT dinucleotide at
the correct exon-intronborder, presumablybecauseof addi-
tional sequences in the endogenous gene context.
Until now, only two dinucleotides have been thought to
be recognized by the U2-dependent spliceosome as 50ss in
mammalian genomes, GT (>99%) and GC (0.5%).38,39
Exon recognition with splicing at a TT dinucleotide under
physiological conditions is not known to occur in
mammals at all. There is only one report in the literature
on TT splicing from 1987 that analyzed aþ1G>Tmutation
in the 50ss of the large human b-globin (HBB) intron 2 in
in vitro assays.71 This study in a HBB splicing reporter re-
vealed a new cleavage site at GT in position 1, CAGG/
GTGAGTCT>CAG/GTTGAGTCT. Splicing in this
construct then could be shifted to TT splicing at þ1 upon
insertion of a second site mutation (c.494G>A; CAAG/
TTGAGTCT) that rendered this artificial HBB splice donor
with two mutations very similar to the mutant FANCC
50ss described here. Common to both functional TT splice
sites is their overall high complementarity to U1 snRNA in
the TT register, which is considerably above the average
HBond score of all human annotated 50ss. Calculated
with GT instead of TT, the FANCC and HBB second site
mutations have HBond scores of 18.7 and 18.2, respec-
tively. Because only 10% of our data set of annotated
human 50ss have an HBond score of R 18.2 (S.T. and
H.S., unpublished data), an overall high complementarity
to U1 snRNA in the TT register might be a prerequisite
for TT splicing. This high complementarity would also
apply for the recently described atypical splice-donor
sites,70 where, according to our findings reported here,
splicing should occur at both positions, GT at 1 and TT
at þ1. However, transcripts at TT in þ1 were not described
in this report,70 possibly because of the fact that the RT-
PCR bands of the splice products were not directly
sequenced but cloned into plasmids prior to sequencing,
or because of additional 50ss sequence and context require-
ments, respectively, not identified yet. Given that high
complementarity at least appears to be one prerequisite
for TT splicing and this occurs only in a small percentage
of human 50ss, we caution here that a G>T mutation at
þ1 does not necessarily abrogate functional splicing in
all cases, because thesemutant noncanonical TT 50ss mightan Journal of Human Genetics 87, 480–493, October 8, 2010 489
be recognized by an endogenous, as-yet-unidentified spli-
ceosomal U1 snRNA.
Recently, expression of a U1 snRNA variant, U1A7, that
is complementary to the mutant FANCC TT 50ss was iden-
tified in HeLa cells.72 This U1A7 snRNA, however, did not
enable TT splicing, neither in our own analyses (data not
shown) nor in the work by Roca and Krainer,70 most likely
because of a nonfunctional snRNA body, thus suggesting
that this U1A7 snRNA might be a transcript of a pseudo-
gene.70 Alternatively, the U1A7 snRNP might be delayed
in its biogenesis, and thus its suppression capability might
simply not have been detected in the transient transfec-
tion assays.
In the FA-C patients with the c.165þ1G>T mutation
described here, we predict that the low levels of normal
mRNA transcript led to low minute levels of normal
FANCC as indicated by the residual FANCD2 monoubiqui-
tination seen upon hydroxyurea (HU) challenge. We
hypothesize that this residual activity of the FA pathway
is the reason for the milder clinical phenotype seen in
these patients compared to other FANCC mutations. This
is in line with findings that in certain FA complementation
groups, such as FA-D2 and FA-D1, at least one hypomor-
phic allele with residual protein activity appears manda-
tory for the survival of patients with biallelic germline
mutations.6,19,73 Remarkably, the exclusive presence of
severe congenital abnormalities in the two patients from
the 640 family with monoallelic c.165þ1G>T mutations
(Table 1) clearly suggests that there might even be an
allele-dose effect visible here.
So far, genetic therapies aimed at correcting the under-
lying deficiency in hematopoietic stem cells utilized inte-
grating retroviral vector systems to introduce a normal
cDNA copy of the affected gene into the target cell. In the
present study, we showed that understanding the pheno-
typic consequence of splice-donor mutations at the
mRNA level can be instrumental to develop therapeutic
strategies to correct an aberrantly processed message. Since
the initial report in 1986, compensatory mutations in U1
snRNA have been known to have the capability to suppress
50ssmutations.48 The suppressive efficiency of these altered
U1 snRNAs, however, depends on the individual mutation
and often can only be assessed by functional testing. Using
two different cellular systems with the c.165þ1G>T muta-
tion, HeLa cells with the splicing reporter carrying the
mutant FANCC 50ss and the FANCC-mutated cells with
the endogenous c.165þ1G>T mutation demonstrated
that transfection of the cells with the two TT-adapted U1
snRNA expression plasmids facilitated correct exon2 recog-
nition for both U1 snRNAs, thereby increasing the fraction
of FANCC exon 2 in-frame spliced pre-mRNA in both
approaches. Although correction of pre-mRNA processing
in minigene constructs with pathogenic splice sites has
been reported by a few groups,49–51,74 correction of the
endogenous transcript and correction of the disease pheno-
type of primary human cells that are deficient in a cellular
transcript has not been reported so far. In a mouse model490 The American Journal of Human Genetics 87, 480–493, Octoberfor spinal muscular atrophy, Meyer et al. elegantly showed
in primary murine cells recently that the germline expres-
sion of an artificial U7 snRNA, which promoted inclusion
of the mutant SMN2 exon 7, can efficiently complement
the muscle tissue and significantly extend the limited life-
span of these animals.74
Here, we showed in primary cells from a patient with
a monogenetic recessive disorder that stable expression of
mutation-adapted U1 snRNAs can be utilized to rescue the
pathological phenotype of these cells. Using lentivirus-
based vectors as delivery systems for the U1 snRNA expres-
sion cassette allows stable integration of the U1 snRNA
expression cassette into the target cell genome in dividing
and nondividing cells,52 e.g., hematopoietic stem cells
andalso retina cells as target cells for genetic correction.75,76
Interestingly, the level of functional restoration of the FA/
BRCA pathway in transduced cells differed between the
two U1 snRNAs that were specifically adapted for the
mutant FANCC exon 2 50ss. The minimally adapted U1
snRNA aTTalmost achieved a correction level of cells where
the normal FANCC cDNA was overexpressed. Although it
would appear likely that an increased complementarity of
the TT-adapted U1 snRNA to the pathogenic 50ss will
more efficiently generate correct transcripts and also reduce
the potential for deleterious off-target effects, surprisingly,
theU1 snRNATTcomwithhigher complementarity seemed
to be less efficient in correcting the cell-cycle arrest in the
primary FA cells. A more advanced strategy combining
our U1 snRNA-based approach with efforts to support U1
snRNAbinding by artificially recruited SRproteins77 should
be further developed to achieve the most efficient correc-
tionof a pathogenic 50ssmutationon theRNA level.Correc-
tion of the endogenous transcript would also obviate the
inability to deliver large genes and ensure that the natural
fine-tuning of the endogenous protein remains intact.
Therefore, correction of pathological mRNA processing at
mutant splice sites might be an attractive gene-therapy
approach for certain FA complementation groups with
either very large genes or toxicity of the overexpressed
genes such as BRCA2(FANCD1)20 or FANCD2.78 This muta-
tion-specific approach might also be feasible in other
genetic disorders with deficiencies in other genes such as
ATM (MIM 607585)79 and NF1 (MIM 613113)80 with
a high percentage of 50ss mutations.Supplemental Data
Supplemental Data include one figure and one table and can be
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